Delivery Order SPE2DR25D1053-SPE2DR26FT742
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,684.70 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 4, 2025, with completion scheduled for June 5, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating open competitive award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and this delivery...
- The Defense Logistics Agency awarded a delivery order valued at $29,158.33 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on September 17, 2025, with completion targeted for September 18, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The pharmaceutical will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $16,181.74 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count packaging) on September 18, 2025, with a completion date of September 19, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single fulfillment under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $32,555.23 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $10,772.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 25, 2025, with completion expected by July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a procurement of pharmaceutical inventory supporting military healthcare operations. The contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count) with a ceiling value of $35,080.14 under a firm fixed-price contract. The award was made on June 2, 2025, with an ultimate completion date of June 3, 2025, and represents a non-competitive delivery order under AmerisourceBergen's existing contract vehicle. Performance will be executed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,789.62 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The order is scheduled for completion by July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $39,787.21 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a completion date of June 2, 2025. This competitively awarded, firm fixed-price contract was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical supply delivery under AmerisourceBergen's broader relationship with the...
- The Defense Logistics Agency (DLA) awarded a $7,848.76 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for RINVOQ ER 30 mg tablets in quantities of 30 units. The contract, issued as a firm fixed-price delivery order with no set-aside designation, is scheduled for completion by September 17, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $18,279.31 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed price, competitively awarded contract without set-aside designation represents a single delivery order under AmerisourceBergen's larger federal pharmaceutical supply framework. The product will be performed at the contractor's corporate office location in...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT742Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $26,261.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging). This competitive, firm fixed-price delivery order was executed on November 7, 2025, with an ultimate completion date of November 10, 2025. The award represents a fulfillment under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 through December 2026. The parent IDC enables AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen has demonstrated sustained capability to meet DLA requirements through competitive procurement across multiple therapeutic domains, supporting the Defense Health Agency and other government healthcare systems with both brand-name and generic medications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.3k | 11/7/25 |